Richard Nkulikiyinka

Richard Nkulikiyinka

Company: Bayer

Job title: Vice President, Executive Advisor of Clinical Development & Operations


Reimagining Inclusion & Exclusion Criteria to Optimize Patient Access & Trial Outcome 10:45 am

Read more

day: Track 2 - Day 2 AM

Panel Discussion: Pursuing the Next Gold Standard in Biomarker Development: Interrogating the Roadmap from Experimental to Validated 12:00 pm

• Developing molecular multi-marker panels to investigate how novel therapeutics interfere with disease processes and validating with longitudinal data • Proteomics, urinary transcriptomics, PROs and microRNA analysis: what correlates with clinical outcome and what is needed for validation? • How aggressively can we pursue surrogate endpoints?Read more

day: Track 2 - Day 1 AM

Advancing & Validating Earlier & More Robust Readouts to Demonstrate Efficacy & Shorten Trials 1:30 pm

• Real-world evidence, PROs, eGFR slope, and albuminuria: how can we design cohort studies to aid validation? • Considering alternative biomarkers as part of readouts: understanding patient quality of life • How far can the industry strive to be aggressive with demonstrating outcomes?Read more

day: Track 2 - Day 1 PM

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.